- In April 2024, Integra LifeSciences has completed the acquisition of Acclarent, Inc., a leader in ENT surgical interventions. This acquisition expands Integra's product portfolio and increases market opportunities, adding USD 1 billion to its total addressable market while enhancing its presence in the ENT device sector
- In September 2024, Stryker has completed the acquisition of NICO Corporation, enhancing its portfolio of minimally invasive solutions for brain tumor removal and intracerebral hemorrhage (ICH) treatment. This strategic addition strengthens Stryker's neurotechnology offerings and aims to improve patient outcomes globally
- In November 2024, Brainlab and Nexstim have entered a collaboration to develop advanced neurosurgery solutions. The partnership focuses on integrating Nexstim's navigated transcranial magnetic stimulation (nTMS) technology with Brainlab's navigation and intraoperative neuromonitoring systems to enhance neurosurgical treatments
- In April 2024, Brainlab has partnered with FUJIFILM Healthcare Americas Corporation as the exclusive distributor of ARIETTA Precision Ultrasound for neurosurgery in the U.S. The collaboration combines advanced ultrasound imaging with Brainlab’s navigation software, offering an integrated solution for real-time insights and improved surgical workflows. The combined system, expected to be FDA-cleared by mid-2024, aims to enhance tumor and lesion resection accuracy
- In August 2024, Elekta has formed a joint venture with AnSheng, its Chinese software partner, to enhance its market position in China. The collaboration aims to improve oncology software solutions, drive product advancements, and boost radiotherapy efficiency and quality for Chinese cancer centers
